Ongoing Clinical Trials for Thymic Carcinoma
There are currently 2 clinical trials investigating new treatment approaches for thymic carcinoma. These studies are testing combinations of immunotherapy and targeted therapy medications in patients who have already received previous treatments. Trials are taking place in several European countries including France, Spain, and Italy.
Clinical trial locations
- France
- Italy
- Spain
Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment
This trial is testing a combination of two immunotherapy medications for patients with several types of rare cancers, including thymic carcinoma and B3 thymomas. The study aims to determine whether the combination of Domvanalimab and Zimberelimab can help patients whose cancer has continued to progress despite receiving at least one standard treatment.
Main inclusion criteria: To participate, you must have been diagnosed with one of five specific rare cancers, including B3 thymomas or thymic carcinoma. Your cancer must be advanced or have spread to other parts of the body and must have progressed or shown resistance after at least one previous standard treatment. You must be at least 18 years old with a life expectancy of at least 16 weeks. You need to have adequate bone marrow, kidney, and liver function, and be able to perform most daily activities with limited symptoms. You must also be willing to provide a tumor tissue sample and agree to use effective contraception if you are of childbearing age.
Main exclusion criteria: You cannot participate if you do not have one of the five specific rare cancers being studied, if your cancer is not advanced or metastatic, if it has not progressed after at least one standard treatment, if you are under 18 years old, or if you are part of a vulnerable population requiring special protection.
Focus of the trial: The study will evaluate the effectiveness and safety of the combination treatment over a 24-week period. Both medications are given through intravenous infusion directly into a vein. Researchers will monitor how well the treatment controls cancer growth, assess side effects, and measure outcomes such as progression-free survival and overall survival. The trial will group patients according to their specific cancer type to better understand how the treatment works for each condition.
Investigational drugs: Domvanalimab is an antibody-based medication that helps the immune system recognize and attack cancer cells by blocking proteins that allow cancer to hide from immune defenses. Zimberelimab works similarly by targeting proteins that prevent the immune system from attacking cancer. Together, these medications aim to enhance the body’s natural ability to fight cancer more effectively.
Study on Pembrolizumab and Lenvatinib for Patients with Pre-Treated Thymic Carcinoma and B3-Thymoma
This clinical trial is investigating the combination of two medications for patients with thymic carcinoma and B3-thymoma who have already received previous treatments. The study will test whether Pembrolizumab combined with Lenvatinib can effectively control these rare cancers and help patients live longer without their disease worsening.
Main inclusion criteria: You must have been diagnosed with relapsed or recurrent B3-thymoma or thymic carcinoma that cannot be cured with surgery or radiation therapy. You need to be at least 18 years old and have already received at least one line of platinum-based chemotherapy for advanced disease. You must have adequate bone marrow and organ function, and your cancer must have shown progression after previous therapy. You should be able to carry out most normal activities with only limited symptoms, and have a life expectancy of at least 3 months. If you are a woman of childbearing age, you cannot be pregnant or breastfeeding and must agree to use birth control. You must also test negative for Myasthenia Gravis and be able to provide a tumor tissue sample.
Main exclusion criteria: You cannot participate if you have a type of cancer other than B3-thymoma or thymic carcinoma, if you have never been treated before for your cancer, if your cancer has not returned or worsened after treatment, if you are outside the required age range, or if you are part of a vulnerable population.
Focus of the trial: The study will last up to 24 months and aims to measure how long patients can live without their disease getting worse over a five-month period. Pembrolizumab will be given as an intravenous infusion once every three weeks, while Lenvatinib will be taken daily as oral capsules. Throughout the trial, regular monitoring will assess how the cancer responds to treatment, including any reduction in tumor size, as well as overall survival rates and treatment safety.
Investigational drugs: Pembrolizumab is an immunotherapy medication that helps the immune system fight cancer by targeting a protein called PD-1 on immune cells, allowing them to better recognize and attack cancer. Lenvatinib is a targeted therapy that blocks proteins needed for cancer cells to grow and spread, effectively limiting the tumor’s ability to receive nutrients and oxygen. Together, these medications aim to provide a more effective treatment approach for patients whose cancer has not responded well to previous therapies.
Summary
Currently, two clinical trials are available for patients with thymic carcinoma in Europe. Both studies focus on patients who have already received previous treatments and whose cancer has progressed or recurred. The trials are testing combination therapies that pair immunotherapy medications with either another immunotherapy drug or a targeted therapy.
The first trial is available only in France and includes patients with thymic carcinoma as part of a broader study of five rare cancer types. The second trial has a wider geographic reach, operating in France, Spain, and Italy, and focuses specifically on thymic carcinoma and B3-thymoma patients.
Both studies require participants to have advanced or metastatic disease that has not responded adequately to standard platinum-based chemotherapy. They share similar eligibility requirements regarding age, organ function, and performance status. The trials represent efforts to find new treatment options for these rare cancers, which have limited therapeutic alternatives once standard treatments fail.
